1056613-51-4

Basic information

• Product Name: ethyl 4-(5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoyloxy)butanoate
• Synonyms: ethyl 4-(5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoyloxy)butanoate
• CAS NO: 1056613-51-4
• Molecular Weight: 444.893
• Mol File: 1056613-51-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: ethyl 4-(5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoyloxy)butanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoyloxy)butanoate(1056613-51-4)
• EPA Substance Registry System: ethyl 4-(5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoyloxy)butanoate(1056613-51-4)

Safety Data

• Hazardous Substances Data: 1056613-51-4(Hazardous Substances Data)

Upstream product

• 2969-81-5 Ethyl 4-bromobutyrate 
• 54-31-9 4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid 

Downstream Products

• 1056613-37-6 4-(5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoyloxy)butanoic acid 

Relevant articles and documents

THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS

Therapeutic amine-arylsulfonamide conjugate compounds, of the general formula: wherein R′ is [D-W-], hydroxyl, or alkoxyl; R″ is independently [D-W′-], hydrogen, alkoxy, alkyl, cycloalkyl, alkenyl, alkynyl or aryl, or R″ and R″ together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7- or 8-membered ring optionally containing one or two further heteroatoms independently selected from nitrogen, oxygen and sulfur; D is independently a therapeutic amine radical comprising at least one nitrogen atom and optionally at least one oxygen atom coupled to W or W′ by a nitrogen or oxygen atom; W and W′ are a chemical bond or linker; wherein either R′ is [D-W-] or at least one R″ is [D-W′-], and pharmaceutically acceptable esters, amides, salts or solvates thereof, pharmaceutical compositions containing same, methods for their preparation, and their use in treating psychiatric, neurologic and metabolic disorders are disclosed.